- Biogen's high-risk bet on Alzheimer's a potential game changer
- 4Q preview: Amgen, Biogen, BMS, Celgene, Novartis, Pfizer and Roche
- INTERVIEW: Pre Diagnostics takes new approach to Alzheimer's blood test
- US Capitol Capsule: FDA barks about state restrictions, but where's the bite?
ANALYSIS Other Informa Analysis